Our Manager, Juan Buela and Elia Alvarez, our Senior Scientist, will be attending UEG Week 2025 in Berlin (October 4–7), and we are pleased to share that we will be presenting a poster entitled: “PP0371: SRB3 DEMONSTRATES ROBUST EX VIVO EFFICACY IN BIO-EXPOSED IBD PATIENTS AND CORRELATES WITH DISEASE ACTIVITY.”
In this study, our anti-CCR9 antibody demonstrated potent ex vivo activity in IBD patient samples, achieving robust depletion of CD4⁺CCR9⁺ T cells and a significant reduction of pro-inflammatory cytokines. These effects were observed in both naïve and biologic-exposed patients and strongly correlated with disease activity, validating its therapeutic potential across clinically relevant populations.
